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Introduction
Faced with escalating health-care costs, in 2003 the Ontario
Ministry of Health and Long-Term Care (MOHLTC) decided to
embark on a new evidence-based platform for decision-making
around medical devices, procedures, and programs. This new
venture was predicated on the belief that assessment of technolo-
gies using a more systematic and rigorous process could improve
efﬁciencies in the health-care system, potentially control rising
health-care costs, and ultimately improve the overall health of
Ontarians. In the case where the evidentiary base for a new
technology is strong and fairly conclusive, making recommenda-
tions about reimbursement, implementation, or uptake of the
technology is relatively straightforward. However, what if the
evidentiary base is of poor quality, conﬂicting, not based on “real
world” effectiveness studies or there are concerns about imple-
mentation and uptake of the technology for a particular jurisdic-
tion? For example, economic evaluation evidence may exist, but
because of known differences in unit costs, practice patterns, or
patient preferences across jurisdictions, this might affect the
transferability of economic evaluation data across jurisdictions.
There may even be concerns about the generalizability of clinical
evidence from other jurisdictions for local decision-making
needs. For example, differences in patient characteristics like
demographics or rates of compliance with therapies, or provider
characteristics such as level of expertise or training, or health-
care system characteristics like payment incentives or available
infrastructure, can all affect whether, and to what extent, a
technology works in a particular jurisdiction. In these cases,
assessing the technology using local context-speciﬁc data collec-
tion may be necessary.
The Programs for Assessment of Technology inHealth (PATH)
Research Institute is the longest established group undertaking
conditionally funded ﬁeld evaluations (CFFEs) of health-care
technologies in Ontario. CFFEs are safety, efﬁcacy, effectiveness,
or cost-effectiveness studies conducted in the “real world” (i.e.,
more pragmatic) and where funding for the technology or use of
the technology is conditional on sites or professionals participat-
ing in data collection for evaluation purposes. There are other
groups in Ontario conducting CFFEs and each research group not
only addresses slightly different levels of decision uncertainty,
but each group also approaches and conducts CFFEs in slightly
different ways. The CFFE process used by PATH, illustrative
examples of completed CFFEs and their impact on policy and
reimbursement in the province are discussed. Finally challenges
for government and researchers are highlighted with some con-
clusions for moving forward.
Ontario’s Evidence-Based Health Technology
Assessment (HTA) Process
An overview of Ontario’s evidence-based HTA process and the
role of CFFEs are provided in Figure 1. The process begins when
a health-care organization, health-care facility or health-care
provider requests that the MOHLTC consider purchasing or
reimbursing a new technology in the province. The funding
requests for surgical or diagnostic procedures, devices or prod-
ucts, or new programs or services are submitted to a division of
the MOHLTC called the Medical Advisory Secretariat (MAS),
which conducts an initial scan of the technology and prioritizes
using a standardized scoring algorithm. This initial scan and
scoring is then presented to the Ontario Health Technology Advi-
sory Committee (OHTAC), which meets once a month to review
evidence around technologies and makes recommendations to
the Deputy Minister of Health. OHTAC was formed in 2003 to
create an evidence-based single point of entry for the uptake and
diffusion of health technologies in the province and consists of
clinical epidemiologists, clinicians, health economists, health
policy analysts, health services researchers, bioethicists, senior
hospital administrators, and representatives from the Ontario
Hospital Association, the Ontario Medical Association, Medical
Device Manufacturing Association, and community-based
health-care programs. Based on the initial scan and prioritiza-
tion, OHTAC may reject the request for review, request more
information or may decide that MAS proceed to conduct a
Health Technology Policy Analysis (HTPA) around the technol-
ogy. An HTPA is completed internally by MAS within 16 weeks,
where the technology’s safety, efﬁcacy, effectiveness, and cost-
effectiveness are reviewed. Guided by a rating of the technology
using the Grades of Recommendation, Assessment, Development
and Evaluation (GRADE), the evidence around the technology is
deliberated by OHTAC at which point OHTAC may make a
policy recommendation regarding the uptake and diffusion of the
technology. OHTAC may also conclude that there is not enough
information to make an evidence-based decision, and recom-
mend that a CFFE be undertaken.
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Role of CFFEs in Ontario’s Evidence-Based Process
As shown in Table 1, OHTAC’s decision uncertainty around a
technology may be based on a lack of conclusive evidence on
quality, safety, efﬁcacy, effectiveness, or cost-effectiveness. These
categories of uncertainty are akin to what are referred to as the
“hurdles for reimbursement” decision-making for drugs. For
example, there may be concerns that the technology may poten-
tially harm patients or health-care providers and, in this case, a
CFFE may be conducted to assess safety or develop guidelines or
standards of practice for use of the technology. Similarly, there
may be concerns about whether the technology could work even
under ideal experimental trial conditions and, in this case, a
CFFE may be recommended to assess the efﬁcacy of the technol-
ogy (e.g., an explanatory randomized controlled trial (RCT)).
There may also be concerns about whether the technology will
work in “real world” practice and it may be recommended that
a pragmatic RCT or observational study be undertaken. And
ﬁnally, there may be concerns over value for money of the tech-
nology and it may be recommended that a cost-effectiveness
analysis be undertaken where resource use, practice patterns,
unit costs, and patient preference information are collected to
help reduce uncertainty.
Once a CFFE is commissioned, a study team is put together
based on key opinion leaders in the province and a protocol is
developed to collect the evidence needed to reduce decision
uncertainty. The CFFEs not only vary in the uncertainty being
addressed, but also vary considerably in terms of study design,
outcomes measured, study duration, sample size, and site partici-
pation. To date, CFFEs have ranged in duration from about 1 to
4 years from study initiation to completion.
Examples of PATH’s Completed CFFEs
The PATH Research Institute has been in existence since 2003.
During the pilot phase of this program, PATH initiated three
CFFEs per year and is now initiating four new CFFE per year.
Most of the CFFEs conducted by PATH have either been efﬁcacy,
effectiveness, or cost-effectiveness evaluations; however, PATH
has also been actively involved in developing general disease
policy models, which can be used to assess the cost-effectiveness
of a number of alternative treatment alternatives at the same time
using a common disease modeling platform. For illustrative pur-
poses, examples of two completed CFFEs are presented below,
along with their subsequent impact on policy in the province.
MAS prioritization of technology
OHTAC reviews list of technologies
Request further information Request HTA from MAS
Reject request for review
16 week review by MAS
OHTAC reviews HTA evidence
Policy recommendation to 
Deputy Minister of Health
Too much decision uncertainty for making evidence-based recommendations 
(request for conditionally funded field evaluation -CFFE)
Quality Safety Efficacy Effectiveness Cost-effectiveness
Requests for technology reviews/request for technology reimbursement from
MOHLTC, health-care organizations or health-care facilities/providers
-
Figure 1 Overview of Ontario’s evidence-based
HTA process and the role of conditional funded
ﬁeld evaluations. CFFE: Conditionally Funded Field
Evaluation, HTA: Health Technology Assessment;
MAS:MedicalAdvisory Secretariat;MOHLTC:Min-
istry of Health and Long-Term Care; OHTAC:
Ontario Health Technology Advisory Committee
[1].
Table 1 Attributes of technologies, questions asked, uncertainty faced by decision makers, and type of conditionally funded ﬁeld evaluations used to
reduce decision uncertainty [2]
Attribute of technology Questions HTAs typically address Typical uncertainty in decision-making Types of CFFEs used to address uncertainty
Quality Is the technology consistent and of high
quality?
Lack of quality evidence or inconsistency
in quality of the technology
Technology quality assurance assessments
Safety Does the technology harm patients or
health-care professionals?
Safety concerns in general or in
context-speciﬁc application of the
technology
Safety assessments, development of
guidelines or standards of practice
Efﬁcacy Can the technology work under ideal
experimental trial conditions?
Poor quality evidence, lack of evidence,
or conﬂicting evidence of efﬁcacy
Explanatory RCTs
Effectiveness Does the technology work in “real world”
practice?
Concerns over generalizability of efﬁcacy
evidence or transferability of clinical
evidence from another jurisdiction
Pragmatic RCTs, observational studies
(e.g., cohort, registries)
Value for money Is the technology cost-effective Compared
with alternative ways of treating patients?
Concerns over transferability of
economic and patient preference
evidence from another jurisdiction
Effectiveness studies including collection
of resource use, practice pattern, unit
cost and patient preference information
CFFE, conditionally funded ﬁeld evaluation; HTA, health technology assessment; RCT, randomized controlled trial.
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Drug-Eluting Stents vs. Bare Metal Stents for Coronary
Artery Disease
Early trials of drug-eluting stents (DES) suggested that this was a
very effective new technology. These data led to considerable
pressure from health professionals and professional associations
on government to comprehensively replace bare metal stents with
DES. It was suggested that an immediate substitution of the
technologies in the range of 60% of cases, followed by a gradual
phase-in over a few years to achieve 100% usage of the new
technology, would be appropriate. However, based on reports in
the literature, OHTAC had concerns about the generalizability of
the clinical trial results to patients in the “real world.” To address
these concerns, PATH, in combination with clinical opinion
leaders in the province and key stakeholders conducted a study
where DESs were conditionally funded in a large study of almost
20,000 patients to determine the relative effectiveness of DES in
different patient populations. The study was designed based on
input from key clinical experts, from the Ontario Cardiac Care
Network and from consultation with both suppliers of DESs in
the province at the time of the study. It was found that the
effectiveness of DES varied by patient characteristics and based
on these study results, OHTAC recommended that DES should
be offered to high-risk patients only (i.e., patients with diabetes
and long or narrow lesions).
The policy impact of OHTAC’s recommendation was imme-
diate and funding was built into subsequent year budgets. Expen-
ditures on bare metal and DES in the province prior to, and
during, the CFFE are shown in Figure 2. Expenditure forecasts
based on stent volumes in the province in the absence of DES
funding are shown as the trend time line, while actual expendi-
tures, including the CFFE, are shown as cumulative bar charts.
As a result of OHTAC’s recommendations based upon the ﬁnd-
ings from the CFFE, funding for stents in the province was $38
million in 2006–2007. This level of funding contrasts sharply to
what the province would have been spending on stents without
controlled diffusion of the technology. Based on uptake rates of
90% (i.e., similar to what happened in the United States with no
diffusion control), Ontario spent $22 million less on stents for
the 2006–2007 ﬁscal year alone (as shown in the second panel in
Fig. 2). Compared with the cost of conducting the study at
approximately $0.5 million, the beneﬁts in terms of cost-savings
for 2006–2007 alone were substantial, and this does not even
account for potential cost-savings moving forward into future
ﬁscal years.
Endovascular Repair (EVAR) of Abdominal Aortic
Aneurisms (AAA)
EVAR was ﬁrst introduced in 1991 and since then, its use as a
treatment for AAA has become widespread. At the time OHTAC
considered funding for EVAR in the province, no large RCTs had
been conducted comparing EVAR with open surgical repair
(OSR) and there were concerns about which patients could
beneﬁt most from EVAR (i.e., patients at low or high risk for
surgical complications) and what was the long term safety of
EVAR. As a result, PATH undertook a CFFE to address these
decision uncertainties. It was found that EVAR was slightly cost
saving and resulted in improved patient outcomes compared with
OSR. Based on these CFFE ﬁndings, OHTAC recommended that
there should be increased access to EVAR for patients at high risk
for surgical complications, including operative mortality. As with
DESs, the policy implications of the study happened quickly:
EVAR was changed from an uninsured to an insured service; a
physician billing code was introduced; hospitals restructured
their operations to accommodate EVAR; and hospitals began
receiving program-speciﬁc funding on top of their global
budgets. The overall result of the CFFE for Ontario was a modest
saving in health-care spending for the estimated 635 high risk
AAA cases per year, while at the same time improving patient
overall outcomes and quality of life.
Challenges
Although very successful in changing behavior and inﬂuencing
policy and funding changes in the province, there have been
challenges faced when trying to implement the CFFE program in
Ontario and a number of lessons have been learned. These chal-
lenges relate to funding, timing, and to the conduct of the studies
themselves.
Funding
The biggest challenge for government is ﬁnding the resources to
fund the infrastructure associated with an evidence-based
decision-making platform and process, which can also include
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Figure 2 Illustrative example of monetary impact
of CFFE research in Ontario:Actual and projected
expenditures ($Cdn) on bare metal and drug
eluting stents in Ontario, by year [2].
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the option of funding for the conduct of CFEEs of technologies
with uncertain risks, beneﬁts and costs. For example, the ﬁeld
evaluation program in Ontario is modestly funded at about
$250,000 per ﬁeld study for core support for PATH and an
additional $250,000 per evaluation for the ﬁeld work itself (e.g.,
research nurses, primary data collection). Although $500,000
per evaluation is a very reasonable cost for conducting primary
data collection studies, the overall cost of such a program can
become large if there are a number of CFFEs undertaken each
year. However, given the political will, there are a number of
potential funding sources. For example, although it is well rec-
ognized that it is difﬁcult to remove ineffective or obsolete tech-
nologies from a health-care system, there is potentially a large
source of funds that can be generated through the adoption of an
evidence-based process that includes removal of these technolo-
gies. Another potential source of funding for ﬁeld evaluations is
from the cost-savings generated by controlled diffusion of a new
technology. As demonstrated for DESs, this strategy generated
millions of dollars of cost avoidance that could prudently be
re-invested back in the CFFE evidence-generating process rather
than simply being absorbed by the health-care system. Another
potential source of funding is from reduced out-of-province pro-
cedures. For example, instead of paying for procedures that are
conducted in the United States because they are determined to be
“medically necessary” but not available in Ontario, these proce-
dures could be made available in Ontario as part of a CFFE.
Finally, ﬁnancing through cost-sharing in the form of unrestricted
grants, or provision of the technology or the supplies associated
with the use of technology, on an experimental basis by technol-
ogy manufacturers could be encouraged. As part of the PATH’s
CFFE process, industry stakeholders are consulted for advice
around possible study designs and use of the technology during
the evaluation (e.g., training and level of experience). Possible
ﬁnancial or “in kind” support from industry stakeholders is
facilitated if they are consulted early, and throughout, the CFFE
process.
Timing
One of the obstacles facing government is timing needed for the
conduct of CFFE. Well designed and conducted CFFEs are
similar to any clinical trial and often take considerable time
before results become available. With a typical three- to ﬁve-year
political cycle, there is often tension between research and politi-
cal needs as senior management of government typically try to
enforce a quick turnaround of research studies and this is not
always conducive to conducting the high quality evaluations that
are required to inform health policy. The process beneﬁts hugely
from the presence of champions within senior management of
government who understand the importance of research and the
need for a long-term perspective when conducting the high
quality research studies that are needed in order to be accepted
by the various stakeholders of the technology.
Research Conduct
The biggest concern from a research perspective is the compro-
mising of scientiﬁc rigor because of time pressures and restric-
tions. By nature, CFFE is a lengthy complex process. It requires
the creation of working groups made up of key stakeholders and
opinion leaders who are involved in designing the study ques-
tions and methods from the beginning of the process. Then there
is protocol development, sample size and site determination, case
report form development, contracts with sites and investigators
and dealing with multiple research ethics board (REB) submis-
sions. For example in one study, almost 100 REBs were involved.
It is worth noting that some studies require large sample sizes,
some require long follow-up periods and some require a range of
outcomes in order to achieve important and valid data, with
study initiation often subject to contractual and legal delays.
PATH’s due diligence systems require that all studies go
through a peer review process, as well as a number of other
quality assurance activities that PATH has insisted upon. For
example, consistent training of health-care professionals with
respect to the technologies has been essential to ensure that the
technology is being used safely. At times this may be done with
the support of the manufacturer where alternative training pro-
grams are not available. In addition, a number of procedures
around the actual conduct and reporting of the study results are
in place to substantiate the validity of our results in the event that
the assessment of the technology is against the perception and
desires of key stakeholders associated with the technology. Above
all else, the CFFEs have to be relevant, rigorous, conclusive and
defensible.
Closing Remarks
Although we have only a limited number of completed CFFEs to
date, all of the studies have been very successful, as government,
researchers and health-care professionals have all worked in
harmony toward a common goal. Furthermore, it is noteworthy
that local data collection appears to carry signiﬁcant weight
within the medical community, who accept that “real world”
patient cohorts in a speciﬁc setting may be signiﬁcantly different
from clinical trial patient cohorts. Very encouragingly, despite a
continuous background of tension around funding of ﬁeld evalu-
ations and time to achieve results, government has been very
receptive to policy recommendations arising from CFFEs. Of
even more policy relevance is the fact that the Ontario govern-
ment has responded by changing policy and increased funding
for all technologies where OHTAC has provided a positive rec-
ommendation based on ﬁndings from a CFFE.
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